Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1039/j39670000701 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fabrication of glipizide loaded polymeric microparticles; in-vitro and in-vivo evaluation.
PLoS One
January 2025
Faculty of Pharmacy, Sardar Bahadur Khan Women University Quetta, Quetta, Pakistan.
Controlled-release microparticles offer a promising avenue for enhancing patient compliance and minimizing dosage frequency. In this study, we aimed to design controlled-release microparticles of Glipizide utilizing Eudragit S100 and Methocel K 100 M polymers as controlling agents. The microparticles were fabricated through a simple solvent evaporation method, employing various drug-to-polymer ratios to formulate different controlled-release batches labeled as F1 to F5.
View Article and Find Full Text PDFComputational insights into marine natural products as potential antidiabetic agents targeting the SIK2 protein kinase domain.
SAR QSAR Environ Res
December 2024
Structural Biology and Biocomputing Lab, Department of Bioinformatics, Alagappa University, Karaikudi, India.
Diabetes mellitus (DM) affects over 77 million adults in India, with cases expected to reach 134 million by 2045. Current treatments, including sulfonylureas and thiazolidinediones, are inadequate, underscoring the need for novel therapeutic strategies. This study investigates marine natural products (MNPs) as alternative therapeutic agents targeting SIK2, a key enzyme involved in DM.
View Article and Find Full Text PDFPhysiologically based pharmacokinetic (PBPK) modeling of gliclazide for different genotypes of CYP2C9 and CYP2C19.
Arch Pharm Res
January 2025
College of Pharmacy, Dongguk University-Seoul, Goyang, 10326, Republic of Korea.
Article Synopsis
- Gliclazide is a medication for type 2 diabetes, primarily metabolized by genetic variations in the CYP2C9 and CYP2C19 enzymes.
- A physiologically based pharmacokinetic (PBPK) model was developed to analyze how these genetic differences affect gliclazide's effects in patients.
- The model accurately predicted drug concentration levels in the bloodstream, meeting standard evaluation criteria and potentially paving the way for personalized treatment plans based on genetic profiles.
Neuroendocrine tumors and diabetes mellitus: which treatment and which effect.
Endocrine
January 2025
Unit of Endocrinology, Department of Clinical and Molecular Medicine, ENETS Center of Excellence, Sapienza University of Rome, Rome, Italy.
Diabetes mellitus (DM) and neuroendocrine tumors (NET) can exert unfavorable effects on each other prognosis. In this narrative review, we evaluated the effects of NET therapies on glycemic control and DM management and the effects of anti-diabetic therapies on NET outcome and management. For this purpose, we searched the PubMed, Science Direct, and Google Scholar databases for studies reporting the effects of NET therapy on DM as well as the effect of DM therapy on NET.
View Article and Find Full Text PDFAnti-diabetic agents and the risks of dementia in patients with type 2 diabetes: a systematic review and network meta-analysis of observational studies and randomized controlled trials.
Alzheimers Res Ther
December 2024
Department of Endocrinology and Metabolism, Peking University People's Hospital, 100044 No.11 Xizhimen South Street, Xicheng District, Beijing China, 100044, People's Republic of China.
Objective: To evaluate the association between anti-diabetic agents and the risks of dementia in patients with type 2 diabetes (T2D).
Methods: Literature retrieval was conducted in PubMed, Embase, the Cochrane Central Register of Controlled Trials and Clinicaltrial.gov between January 1995 and October 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!